NASDAQ:MDGL

Madrigal Pharmaceuticals - MDGL Stock Forecast, Price & News

$73.34

+3.13 (+4.46%)

(As of 08/12/2022 12:00 AM ET)

Add

Compare

Today's Range: $70.21
▼
$74.27
50-Day Range: $60.57
▼
$84.65
52-Week Range: $52.33
▼
$105.93

Volume: 183,843 shs
Average Volume: 175,394 shs
Market Capitalization: $1.25 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $161.00

Madrigal Pharmaceuticals MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.80 Rating Score
Upside/Downside: 119.5% Upside
$161.00 Price Target
Short Interest: Bearish
12.89% of Float Sold Short
Dividend Strength: N/A
Sustainability: -1.11
Upright™ Environmental Score
News Sentiment: 1.39
Based on 8 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($15.19) to ($12.28) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.38 out of 5 stars

Medical Sector

315th out of 1,135 stocks

Pharmaceutical Preparations Industry

160th out of 557 stocks

3.4

Analyst's Opinion

Consensus Rating
Madrigal Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $161.00, Madrigal Pharmaceuticals has a forecasted upside of 119.5% from its current price of $73.34.
Amount of Analyst Coverage
Madrigal Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
12.89% of the float of Madrigal Pharmaceuticals has been sold short.
Short Interest Ratio / Days to Cover
Madrigal Pharmaceuticals has a short interest ratio ("days to cover") of 8.4.
Change versus previous month
Short interest in Madrigal Pharmaceuticals has recently increased by 3.23%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Madrigal Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Madrigal Pharmaceuticals does not have a long track record of dividend growth.

4.5

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Madrigal Pharmaceuticals has received a 69.32% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for physiological diseases " and "Preclinical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for Madrigal Pharmaceuticals is -1.11.

3.5

News and Social Media Coverage

News Sentiment
Madrigal Pharmaceuticals has a news sentiment score of 1.39. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 8 news articles for Madrigal Pharmaceuticals this week, compared to 1 article on an average week.
MarketBeat Follows
3 people have added Madrigal Pharmaceuticals to their MarketBeat watchlist in the last 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Madrigal Pharmaceuticals insiders have not sold or bought any company stock.
Percentage Held by Insiders
29.71% of the stock of Madrigal Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
81.83% of the stock of Madrigal Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Madrigal Pharmaceuticals are expected to grow in the coming year, from ($15.19) to ($12.28) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Madrigal Pharmaceuticals is -4.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Madrigal Pharmaceuticals is -4.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Madrigal Pharmaceuticals has a P/B Ratio of 15.03. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Madrigal Pharmaceuticals (NASDAQ:MDGL) Stock

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.

Madrigal Pharmaceuticals Price Performance

Shares of NASDAQ:MDGL traded up $3.13 during midday trading on Friday, reaching $73.34. The company's stock had a trading volume of 183,843 shares, compared to its average volume of 175,394. Madrigal Pharmaceuticals has a fifty-two week low of $52.33 and a fifty-two week high of $105.93. The company has a market capitalization of $1.25 billion, a P/E ratio of -4.87 and a beta of 1.05. The company has a debt-to-equity ratio of 0.58, a current ratio of 2.55 and a quick ratio of 2.55. The business's fifty day simple moving average is $71.22 and its 200-day simple moving average is $77.41.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on MDGL shares. Canaccord Genuity Group upped their price target on shares of Madrigal Pharmaceuticals from $133.00 to $151.00 and gave the company a "buy" rating in a report on Thursday, May 12th. B. Riley downgraded Madrigal Pharmaceuticals from a "buy" rating to a "neutral" rating and dropped their price objective for the stock from $131.00 to $75.00 in a report on Friday, July 8th. Finally, Oppenheimer lowered their price target on Madrigal Pharmaceuticals from $180.00 to $170.00 in a report on Tuesday, May 10th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $161.00.

Receive MDGL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Madrigal Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

MDGL Stock News Headlines

August 5, 2022 | nasdaq.com

Bullish Two Hundred Day Moving Average Cross - MDGL

August 4, 2022 | finance.yahoo.com

Madrigal Pharmaceuticals Provides Clinical and Business Updates and Reports 2022 Second Quarter Financial Results

July 25, 2022 | americanbankingnews.com

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Receives $162.29 Consensus Target Price from Analysts

July 22, 2022 | americanbankingnews.com

Madrigal Pharmaceuticals (NASDAQ:MDGL) Shares Gap Up to $69.80

June 27, 2022 | nasdaq.com

MDGL Crosses Below Key Moving Average Level

June 27, 2022 | finance.yahoo.com

Analysts Believe Madrigal's Resmetirom Shows Impressive Overall Profile In Liver Fibrosis

June 25, 2022 | finance.yahoo.com

Madrigal Pharmaceuticals Presents Late-Breaking Phase 3 NASH Data and Multiple Oral Abstracts at EASL’s International Liver Congress™

June 6, 2022 | finance.yahoo.com

Madrigal Pharmaceuticals Supports International NASH Day on June 9

June 2, 2022 | finance.yahoo.com

Madrigal Pharmaceuticals Announces Participation at Three Upcoming Investor Conferences

May 17, 2022 | finance.yahoo.com

Madrigal Pharmaceuticals Announces Participation at Two Upcoming Investor Conferences

May 9, 2022 | seekingalpha.com

Madrigal Pharmaceuticals, Inc. (MDGL) CEO Paul Friedman on Q1 2022 Results - Earnings Call Transcript

May 9, 2022 | seekingalpha.com

Madrigal Pharmaceuticals GAAP EPS of -$3.36 beats by $0.20

May 9, 2022 | finance.yahoo.com

Madrigal Pharmaceuticals Provides Clinical and Business Updates and Reports 2022 First Quarter Financial Results

April 28, 2022 | finance.yahoo.com

Madrigal Pharmaceuticals to Announce First Quarter 2022 Financial Results and Provide Clinical and Business Updates on May 9

April 19, 2022 | seekingalpha.com

Madrigal: NASH Data In Q4 Is The Key

April 18, 2022 | nasdaq.com

Madrigal Pharmaceuticals Becomes Oversold (MDGL)

April 12, 2022 | finance.yahoo.com

10 Best Stocks to Buy Now According to Billionaire Nicholas Pritzker’s Tao Capital

April 11, 2022 | nasdaq.com

Madrigal Pharmaceuticals (MDGL) Shares Cross Below 200 DMA

March 18, 2022 | nasdaq.com

Notable Friday Option Activity: MDGL, ASAN, LL

March 9, 2022 | finance.yahoo.com

Madrigal Pharmaceuticals to Present at the Oppenheimer Healthcare Conference

February 24, 2022 | seekingalpha.com

Madrigal Pharmaceuticals Q4 net loss widens Y/Y

February 24, 2022 | finance.yahoo.com

Madrigal Pharmaceuticals Provides Business and Clinical Updates and Reports 2021 Fourth Quarter and Full Year Financial Results

February 9, 2022 | nasdaq.com

MDGL Makes Bullish Cross Above Critical Moving Average

January 31, 2022 | reuters.com

Madrigal's drug candidate reduces fatty liver in late-stage NASH trial

January 31, 2022 | finance.yahoo.com

Madrigal Pharma's Kidney Disease Candidate Improves Liver, Cardiovascular Health

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive MDGL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Madrigal Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

MDGL Company Calendar

Last Earnings: 11/04/2021
Today: 8/13/2022
Next Earnings (Estimated): 11/03/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: Biotechnology
Sector: Medical
Current Symbol: NASDAQ:MDGL
CUSIP: 87162T20
CIK: 1157601
Web: www.madrigalpharma.com
Phone: (484) 380-9263
Fax: 781-274-8228
Employees: 71
Year Founded: 2011

Price Target and Rating

Average Stock Price Forecast: $161.00
High Stock Price Forecast: $220.00
Low Stock Price Forecast: $75.00
Forecasted Upside/Downside: +119.5%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.80
Research Coverage: 5 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($15.07)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-241,850,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -155.03%
Return on Assets: -100.64%

Debt

Debt-to-Equity Ratio: 0.58
Current Ratio: 2.55
Quick Ratio: 2.55

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $4.88 per share
Price / Book: 15.03

Miscellaneous

Outstanding Shares: 17,100,000
Free Float: 12,022,000
Market Cap: $1.25 billion
Optionable: Optionable
Beta: 1.05

Social Links

Key Executives

Dr. Paul A. Friedman M.D. (Age 79)
Chairman & CEO
Comp: $1.05M
Dr. Rebecca A. Taub M.D. (Age 70)
Founder, Chief Medical Officer, Pres of R&D and Director
Comp: $854.75k
Mr. Alex G. Howarth (Age 53)
Sr. VP & CFO
Comp: $605.3k
Mr. Brian J. Lynch J.D. (Age 60)
Sr. VP & Gen. Counsel
Comp: $699.28k
Mr. Remy Sukhija (Age 50)
Sr. VP & Chief Commercial Officer
Comp: $720.07k
Dr. Kianoush Motesharei Ph.d. (Age 52)
Sr. VP of Bus. & Corp. Devel.
Mr. Edward Chiang
Sr. VP of Clinical & Technical Operations
Mr. Thomas W. Hare
Sr. VP of Clinical Management
Dr. Robert E. Waltermire Ph.D. (Age 58)
Chief Pharmaceutical Devel. Officer
Dr. Stephen Dodge M.B.A.
Pharm.D., Sr. VP of Global Medical Affairs

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

MDGL Stock - Frequently Asked Questions

Should I buy or sell Madrigal Pharmaceuticals stock right now?: 5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Madrigal Pharmaceuticals in the last year. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" MDGL shares.
View MDGL analyst ratings or view top-rated stocks.
What is Madrigal Pharmaceuticals' stock price forecast for 2022?: 5 brokers have issued 12-month price objectives for Madrigal Pharmaceuticals' shares. Their MDGL share price forecasts range from $75.00 to $220.00. On average, they expect the company's stock price to reach $161.00 in the next year. This suggests a possible upside of 119.5% from the stock's current price.
View analysts price targets for MDGL or view top-rated stocks among Wall Street analysts.
How have MDGL shares performed in 2022?: Madrigal Pharmaceuticals' stock was trading at $84.74 at the beginning of the year. Since then, MDGL shares have decreased by 13.5% and is now trading at $73.34.
View the best growth stocks for 2022 here.
When is Madrigal Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, November 3rd 2022.
View our MDGL earnings forecast.
How were Madrigal Pharmaceuticals' earnings last quarter?: Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) issued its quarterly earnings results on Thursday, November, 4th. The biopharmaceutical company reported ($3.79) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($3.87) by $0.08.
What other stocks do shareholders of Madrigal Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Madrigal Pharmaceuticals investors own include Achillion Pharmaceuticals (ACHN), Exelixis (EXEL), Advaxis (ADXS), Viking Therapeutics (VKTX), Sangamo Therapeutics (SGMO), Amarin (AMRN), CRISPR Therapeutics (CRSP), Intercept Pharmaceuticals (ICPT), Sarepta Therapeutics (SRPT) and Gilead Sciences (gild).

What is Madrigal Pharmaceuticals' stock symbol?: Madrigal Pharmaceuticals trades on the NASDAQ under the ticker symbol "MDGL."
Who are Madrigal Pharmaceuticals' major shareholders?: Madrigal Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Artisan Partners Limited Partnership (1.24%), Jennison Associates LLC (1.07%), FMR LLC (0.96%), Northern Trust Corp (0.67%), Affinity Asset Advisors LLC (0.58%) and Hennion & Walsh Asset Management Inc. (0.35%). Insiders that own company stock include Bay City Capital Llc and Fred B Craves.
View institutional ownership trends.
How do I buy shares of Madrigal Pharmaceuticals?: Shares of MDGL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Madrigal Pharmaceuticals' stock price today?: One share of MDGL stock can currently be purchased for approximately $73.34.
How much money does Madrigal Pharmaceuticals make?: Madrigal Pharmaceuticals (NASDAQ:MDGL) has a market capitalization of $1.25 billion. The biopharmaceutical company earns $-241,850,000.00 in net income (profit) each year or ($15.07) on an earnings per share basis.
When was Madrigal Pharmaceuticals founded?: Madrigal Pharmaceuticals was founded in 2011.
How can I contact Madrigal Pharmaceuticals?: Madrigal Pharmaceuticals' mailing address is 200 BARR HARBOR DRIVE SUITE 400, WEST CONSHOHOCKEN PA, 19428. The official website for the company is www.madrigalpharma.com. The biopharmaceutical company can be reached via phone at (484) 380-9263, via email at ir@madrigalpharma.com, or via fax at 781-274-8228.

This page (NASDAQ:MDGL) was last updated on 8/14/2022 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Madrigal Pharmaceuticals - MDGL Stock Forecast, Price & News

Madrigal Pharmaceuticals MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Madrigal Pharmaceuticals (NASDAQ:MDGL) Stock

Madrigal Pharmaceuticals Price Performance

Wall Street Analyst Weigh In

MDGL Stock News Headlines

MDGL Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

Insiders & Institutions

MDGL Stock - Frequently Asked Questions

Should I buy or sell Madrigal Pharmaceuticals stock right now?

What is Madrigal Pharmaceuticals' stock price forecast for 2022?

How have MDGL shares performed in 2022?

When is Madrigal Pharmaceuticals' next earnings date?

How were Madrigal Pharmaceuticals' earnings last quarter?

What other stocks do shareholders of Madrigal Pharmaceuticals own?

What is Madrigal Pharmaceuticals' stock symbol?

Who are Madrigal Pharmaceuticals' major shareholders?

How do I buy shares of Madrigal Pharmaceuticals?

What is Madrigal Pharmaceuticals' stock price today?

How much money does Madrigal Pharmaceuticals make?

When was Madrigal Pharmaceuticals founded?

How can I contact Madrigal Pharmaceuticals?

MarketBeat Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources

Overall MarketRank^™